Diagnostic Imaging Efficacy In Metastases From Unknown Primary Site – Own Material

• Authors: Angelika Bara , Piotr Pluta , Arkadiusz Jeziorski
• Languages of publication: EN

Abstracts

EN

Cancer of Unknown Primary Origin (CUPO) is defined by the presence of metastatic lesions, diagnosed by means of cytological or pathological evaluation, for which no primary site can be detected during a thorough examination. The clinical investigation, directed at locating the site of the neoplastic lesion, is determined by the results of laboratory tests, imaging procedures, and pathological examinations. It is also essential to conduct a complete medical history and thorough physical examination. The detection of the primary site allowed to introduce specific therapy, which can offer clinical benefits, considering a favorable prognosis.The aim of the study was to assess the range of diagnostic procedures performed in patients with CUPO and efficacy in identifying the primary lesion.Material and methods. Retrospective analysis comprised a group of 29 patients with CUPO, operated between January, 2002 and December, 2011, at the Department of Surgical Oncology, Medical University in Łódź. The study group comprised 16 male and 13 female patients; median age at presentation was 58.3 years (ranging between 30-79 years).Results. Detailed diagnostic management depending on the location of metastatic lesions and their histological type was performed in 20 of the 29 study patients (69%). Considering the remaining 9 (31%) patients detailed diagnostics was not performed, due to the patients' poor general condition. In 55% (11/20) of patients subject to detailed diagnostics, the primary neoplastic lesion was determined.Conclusions. Considering the study group, most patients with cancer of unknown primary origin were characterized by a favorable prognosis, which justified thorough diagnostics, in order to establish the primary neoplastic lesion. The introduction of diagnostic examinations enabled to identify the primary site of the tumor in more than 50% of patients. With the development of imaging methods one can expect improvement of unsatisfactory results, considering the detection of primary neoplastic foci.

Keywords

EN

cancer of unknown primary origin; diagnostics

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2015
• Volume: 87
• Issue: 5
• Pages: 245-251

Dates

published

1 - 5 - 2015

received

1 - 3 - 2015

online

10 - 7 - 2015

Contributors

author

Angelika Bara

• Department of Surgical Oncology, Medical University in Łodź, Copernicus Memorial Hospital in ŁódźKierownik: prof. dr hab.

author

Piotr Pluta

• Department of Surgical Oncology, Medical University in Łodź, Copernicus Memorial Hospital in ŁódźKierownik: prof. dr hab.

author

Arkadiusz Jeziorski

• Department of Surgical Oncology, Medical University in Łodź, Copernicus Memorial Hospital in ŁódźKierownik: prof. dr hab.

References

• 1. Litwiniuk M, Krzakowski M, Bujko K et al.: Nowotwory o nieznanym umiejscowieniu pierwotnym. W: Krzakowski M, Dziadziuszko R, Fijuth J i wsp. (red.): Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Medica, Gdańsk: 2011, s. 453-66.
• 2. Pavlidis N, Briasoulis E, Hainsworth J et al.: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39(14): 1990-2005.
• 3. Varadhachary GR, Abbruzzese JL, Lenzi R: Diagnostic strategies for unknown primary cancer. Cancer 2004; 100(9): 1776-85.
• 4. Briasoulis E, Pavlidis N: Cancer of unknown primary origin. Oncologist1997; 2: 42-52.
• 5. Abbruzzese JL, Lenzi R, Raber MN et al.: The biology of unknown primary tumors. Semin Oncol 1993; 20: 238-43.
• 6. Kawasaki H, Yoshida J, Yokose T et al.: Primary unknown cancer in pulmonary hilar lymph node with spontaneous transient regression: report of a case. Jpn J ClinOncol 1998; 28(6): 405-09.
• 7. Bell CW, Pathak S, Frost P: Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. Cancer Res 1989; 49: 4311-15.
• 8. Yuhas JM, Pazmino NH : Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. Cancer Res 1974; 34: 2005-10.
• 9. Varadhachary GR: Carcinoma of unknown primary origin. Gastrointest Cancer Res 2007; 1: 229-35.
• 10. Greco FA: Cancer of unknown primary site. Am Soc Clin Oncol Educ Book 2013; 2013: 175-81.
• 11. Abbruzzese JL, Abbruzzese MC, Hess KR et al.: Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272-80.
• 12. Altman E, Cadman E: An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57: 120-24.
• 13. Pavlidis N: Forty years experience of treating cancer of unknown primary. Acta Oncologica 2007; 46: 592-601.
• 14. Culine S, Kramar A, Saghatchian M et al.: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20(24): 4679-83.
• 15. Culine S: Prognostic factors in unknown primary cancer. Semin Oncol 2009; 36: 60-64.
• 16. Le Chevalier T, Cvitkovic E, Caille P et al.: Early metastatic cancer of unknown primary origin at presentation: a clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 2035-39.
• 17. Mayordomo JI, Guerra JM, Guijarro C et al.: Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 1993; 79: 321-24.
• 18. Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknownprimary: from autopsy to microarray. Eur J Cancer 2007; 43(14): 2026-36.
• 19. Weber A, Schmoz S, Bootz F: CUP (carcinoma of unknown primary) syndrome in head and neck: clinic, diagnostic and therapy. Onkologie 2001; 24(1): 38-43.
• 20. Issing WJ, Taleban B, Tauber S: Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 2003; 260(8): 436-43.
• 21. Kawecki A, Nawrocki S, Golusinski W i wsp.: Nowotwory nabłonkowe narządów głowy i szyi. W: Krzakowski M, Dziadziuszko R, Fijuth J i wsp. (red.): Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Medica, Gdańsk 2011, s. 1-32.
• 22. Pavlidis N, Pentheroudakis G: Cancer of unknown primary site. Lancet 2012; 379(9824): 1428-35.
• 23. Lee DJ, Rostock RA, Harris A: Clinical evaluation of patients with metastatic squamous carcinoma of the neck of occult primary tumor. South Med J 1986; 79: 979-83.
• 24. Lapeyre M, Malissard L, Peiffert D et al.: Cervical lymph node metastasis from an unknown primary: Is a tonsillectomy necessary? Int J Radiat Oncol Biol Phys 1997; 39: 291-96.
• 25. Randall DA, Johnstone PA, Foss RD et al.: Tonsillectomy in diagnosis of the unknown primary tumor of the head and neck. Otolaryngol Head Neck Surg 2000; 122: 52-55.
• 26. Rades D, Kuhnel G, Wildfang I et al.: Localised disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12: 1605-09.
• 27. Hanasono MM, Kunda LD, Segall GM et al.: Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880-85.
• 28. Aassar OS, Fischbein NJ, Caputo GR et al.: Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumor. Radiology 1999; 210: 177-81.
• 29. Greven KM, Keyes JW, Williams DW 3rd et al.: Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-(F-18)fluoro-2-deoxy-D-glucose. Cancer 1999; 86: 114-18.
• 30. Załącznik Nr 4 do Zarządzenia Nr 67/2011/DSOZ Prezesa Narodowego Funduszu Zdrowia z dnia 18 października 2011 r.
• 31. Fizazi K, Greco FA, Pavlidis N et al.: ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 (suppl 6): vi64-68.
• 32. Seve P, Billotey C, Broussolle C et al.: The role of 2-deoxy-2-(F-18)fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109(2): 292-99.
• 33. Kwee TC, Kwee RM: Combined FDG-PET/CT for the detection of unknown primary tumors: systemic review and meta-analysis. Eur Radiol 2009; 19: 731-44.
• 34. Pentheroudakis G, Lazaridis G, Pavlidis N: Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat 2010; 119: 1-11.
• 35. Orel SG, Weinstein SP, Schnall MD et al.: Breast MR Imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999; 212: 543-49.
• 36. Guarischi A, Keane TJ, Elhakim T: Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987; 59: 572-77.
• 37. Chang AE, Karnell LH, Menck HR : The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998; 83: 1664-78.
• 38. Katz KA, Jonasch E, Hodi FS et al.: Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005; 15: 77-82.
• 39. Cormier JN, Xing Y, Feng L et al.: Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006; 106(9): 2012-20.
• 40. Kim HS, Kim EK, Jun HJ et al.: Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer 2010; 10: 167.

Identifiers

DOI

10.1515/pjs-2015-0049